Summary ThromboGenics NV (ThromboGenics) is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The company’s ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT). ThromboGenics’s product pipeline includes THR-409 (ocriplasmin) under evaluation for inducing total posterior vitreous detachment in patients with non-proliferative diabetic retinopathy; THR-317 for diabetic macular edema; THR-687 and THR-149 for diabetic retinopathy. ThromboGenics spun off its oncology research in a joint venture with VIB (Flanders Institute for Biotechnology) into Oncurious NV, which focuses on the treatment of pediatric brain tumors. It has a presence in Belgium, Ireland and the US. ThromboGenics is headquartered in Leuven, Flemish Brabant, Belgium. ThromboGenics NV (THR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over... Research Beam Model: Research Beam Product ID: 1996136 250 USD New
ThromboGenics NV (THR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
 
 

ThromboGenics NV (THR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Category : Pharmaceuticals
  • Published On : August   2017
  • Pages : 43
  • Publisher : GlobalData
 
 
 
Summary

ThromboGenics NV (ThromboGenics) is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The company’s ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT). ThromboGenics’s product pipeline includes THR-409 (ocriplasmin) under evaluation for inducing total posterior vitreous detachment in patients with non-proliferative diabetic retinopathy; THR-317 for diabetic macular edema; THR-687 and THR-149 for diabetic retinopathy. ThromboGenics spun off its oncology research in a joint venture with VIB (Flanders Institute for Biotechnology) into Oncurious NV, which focuses on the treatment of pediatric brain tumors. It has a presence in Belgium, Ireland and the US. ThromboGenics is headquartered in Leuven, Flemish Brabant, Belgium.

ThromboGenics NV (THR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ThromboGenics NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
ThromboGenics NV, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
ThromboGenics Forms Joint Venture with VIB 10
Licensing Agreements 11
ThromboGenics Enters into Licensing Agreement with Galapagos 11
ThromboGenics Enters Into Licensing Agreement With Bicycle Therapeutics 12
ThromboGenics Enters Into Licensing Agreement With Eleven Biotherapeutics 13
ThromboGenics Enters Into Licensing Agreement With Alcon For Ocriplasmin 14
Equity Offering 16
ThromboGenics Completes Private Placement Of Shares For US$103.7 Million 16
ThromboGenics NV - Key Competitors 18
ThromboGenics NV - Key Employees 19
ThromboGenics NV - Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Mar 16, 2017: ThromboGenics Business Update - FY 2016 21
Oct 20, 2016: ThromboGenics Business Update - Q3 2016 25
Aug 25, 2016: ThromboGenics Business Update- H1 2016 28
Corporate Communications 32
Jun 15, 2017: Thomas Clay Appointed Chairman of the Board of Directors 32
Product Approvals 33
Jan 07, 2016: BioInvent announces FDA acceptance of the Investigational New Drug application for the phase I/IIa study with TB-403 33
Other Significant Developments 34
May 11, 2017: ThromboGenics Business Update – Q1 2017 34
May 13, 2016: ThromboGenics Business Update – Q1 2016 37
May 13, 2016: ThromboGenics Business Update - Q1 2016 40
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
ThromboGenics NV, Pharmaceuticals & Healthcare, Key Facts, 2016 2
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ThromboGenics NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ThromboGenics NV, Deals By Therapy Area, 2011 to YTD 2017 8
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
ThromboGenics Forms Joint Venture with VIB 10
ThromboGenics Enters into Licensing Agreement with Galapagos 11
ThromboGenics Enters Into Licensing Agreement With Bicycle Therapeutics 12
ThromboGenics Enters Into Licensing Agreement With Eleven Biotherapeutics 13
ThromboGenics Enters Into Licensing Agreement With Alcon For Ocriplasmin 14
ThromboGenics Completes Private Placement Of Shares For US$103.7 Million 16
ThromboGenics NV, Key Competitors 18
ThromboGenics NV, Key Employees 19
ThromboGenics NV, Other Locations 20
ThromboGenics NV, Subsidiaries 20
List of Figures
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter